As aromatase mediates estrogen production, its inhibition with chemical molecules is considered an effective treatment for estrogen receptor (ER)-positive breast cancer
The FDA 503A and 503B refers to sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which created two separate regulatory pathways for compounded medications: 503A comes from Section 503A - Pharmacy Compounding of the FD&C Act, and it defines the 503A compounding pharmacy pathway 503B comes from Section 503B - Outsourcing Facilities of the FD&C Act and it defines the 503B outsourcing facility pathway Section 503B was established following the 2012 New England Compounding Center (NECC) tragedy, a nationwide fungal meningitis outbreak leading to over 50 deaths, caused by contaminated injectable steroid medications
[DOI] [PubMed] [Google Scholar] 21.Aoi W, Ogaya Y, Takami M, et al
STEP 1 enrolled 1,961 adults with overweight or obesity (BMI of 30 or greater, or 27 or greater with at least one weight-related condition)
The 500 mcg per-capsule dose mirrors the per-day intake used in the bulk of rodent oral studies, and the gastric origin of the parent molecule provides a biological rationale for stability through the GI tract a feature documented across multiple oral-administration preclinical models
